EDAP TMS Reports Third Quarter 2017 Results EDAP's HIFU patient treatment revenues grew 29% compared to third quarter 2016. EDAP received FDA clearance for its Ablatherm Fusion ® late in the quarter. EDAP's cash position remains strong at US $21.3 million on September 30, 2017 LYON, France ,
LYON, France , Dec. 12, 2016 (GLOBE NEWSWIRE) -- EDAP TMS S.A. (NASDAQ:EDAP), the global leader in therapeutic ultrasound today announced that it has retained CG Capital , a leading capital markets development and research firm as their new investor relations counsel.
European Growth Continues, HIFU Division Returns to Profitability Retains Experienced North American Prostate Cancer Leader to Drive USA Programs Lyon, France, August 30, 2007 - EDAP TMS S.A. (Nasdaq: EDAP) , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer
EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies LYON, France , Oct. 30 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces that it has entered into a securities purchase
EDAP TMS S.A. Announces $7.5 Million Placement Lyon, France, July 27, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) announced that it has entered into a securities purchase agreement with selected accredited investors pursuant to which an aggregate of 961,676 of the company's ordinary shares in the form of
EDAP TMS S.A. Announces Exclusive Distribution of New Muscle Trainer Device in Japan Lyon, France, January 30, 2007 - EDAP TMS S.A. (Nasdaq: EDAP ), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development,
